VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Ai on Single-Agent and Combination Therapy in Patients With MDS

Jing Ai, MD
Published: Thursday, Apr 26, 2018



Jing Ai, MD, physician, Levine Cancer Institute, discusses the rationale behind single-agent therapy and the development of combination therapy in patients with myelodysplastic syndrome (MDS).

Ai says that choosing between single agent and combination therapy usually depends on the experience of the treating physician. Single agents are often used in the relapsed/refractory setting, as these patients have already failed 2 or 3 lines of therapy. Physicians turn to whatever has the best biological reason for use, Ai says.

From a clinical trial standpoint, MDS as compared with acute myeloid leukemia (AML) does not receive as much attention, even though the 2 diseases are biologically similar, Ai says. Her hope is that clinical trials for AML extend to patients with MDS to improve upon available treatment.
 


Jing Ai, MD, physician, Levine Cancer Institute, discusses the rationale behind single-agent therapy and the development of combination therapy in patients with myelodysplastic syndrome (MDS).

Ai says that choosing between single agent and combination therapy usually depends on the experience of the treating physician. Single agents are often used in the relapsed/refractory setting, as these patients have already failed 2 or 3 lines of therapy. Physicians turn to whatever has the best biological reason for use, Ai says.

From a clinical trial standpoint, MDS as compared with acute myeloid leukemia (AML) does not receive as much attention, even though the 2 diseases are biologically similar, Ai says. Her hope is that clinical trials for AML extend to patients with MDS to improve upon available treatment.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x